{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:09:25Z","timestamp":1771297765374,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The use of 5-hydroxytryptamine-3 receptor antagonists (5HT<jats:sub>3<\/jats:sub>RA) has long been considered the standard regimen for preventing chemotherapy-induced nausea and vomiting (CINV) prior to hematopoietic stem cell transplantation (HSCT). However, their therapeutic outcomes have been unsatisfactory. NEPA, an oral formulation combining the neurokinin-1 receptor antagonist netupitant and the 5HT<jats:sub>3<\/jats:sub>RA palonosetron, has received regulatory approval for the management of highly and moderately emetogenic chemotherapy. This study aims to compare the efficacy of NEPA with that of 5HT<jats:sub>3<\/jats:sub>RA alone in preventing CINV among patients undergoing multiday conditioning chemotherapy prior to HSCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We conducted a retrospective analysis of patients who underwent HSCT between September 2019 and September 2022. Efficacy outcomes were assessed based on the rates of patients achieving complete response (CR: no emesis and no use of rescue medication), complete control (CC: CR without significant nausea), no vomiting, and no significant nausea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The NEPA group consisted of 106 patients, while the 5HT<jats:sub>3<\/jats:sub>RA group included 107 patients. The NEPA group exhibited significantly higher rates of CR compared to the 5HT<jats:sub>3<\/jats:sub>RA group during the overall phase (71.7% vs. 32.7%, P&amp;lt;0.001), acute phase (78.3% vs. 43.0%, P&amp;lt;0.001), and delayed phase (84.9% vs. 58.9%, P&amp;lt;0.001). Similarly, rates of CC, no vomiting, and no significant nausea were significantly better in the NEPA group across all phases (P&amp;lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>NEPA demonstrated superior efficacy compared to 5HT<jats:sub>3<\/jats:sub>RA in preventing CINV during all phases of multiday conditioning regimens among patients undergoing HSCT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1280336","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:45:50Z","timestamp":1700754350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of netupitant\/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"13","author":[{"given":"Hang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinchuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1448-1","article-title":"Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients\u2019 quality of life","volume":"20","author":"Fern\u00e1ndez-Ortega","year":"2012","journal-title":"Support Care Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2325-x","article-title":"Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers","volume":"23","author":"Van Laar","year":"2015","journal-title":"Support Care Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.114","article-title":"Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT","volume":"45","author":"Musso","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq457","article-title":"Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation","volume":"22","author":"Giralt","year":"2011","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.74.4789","article-title":"Antiemetics: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J Clin Oncol"},{"key":"B6","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2006.n.011","article-title":"Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis","volume":"3","author":"Reddy","year":"2006","journal-title":"Support Cancer Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.peptides.2012.06.010","article-title":"In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant","volume":"37","author":"Rizzi","year":"2012","journal-title":"Peptides"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh","year":"2014","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu096","article-title":"A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy","volume":"25","author":"Gralla","year":"2014","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2012.05.037","article-title":"Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects","volume":"689","author":"Stathis","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"10781552231173863","DOI":"10.1177\/10781552231173863","article-title":"A phase II trial of netupitant\/palonosetron for prevention of chemotherapy-induced nausea\/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation","author":"Bubalo","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0909-2","article-title":"Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study","volume":"55","author":"Di Renzo","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06472-7","article-title":"Netupitant\/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience","volume":"30","author":"Loteta","year":"2022","journal-title":"Support Care Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04180-6","article-title":"Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation","volume":"99","author":"Apolito","year":"2020","journal-title":"Ann Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s44228-022-00012-8","article-title":"Antiemetic strategies in patients who undergo hematopoietic stem cell transplantation","volume":"4","author":"Yuda","year":"2022","journal-title":"Clin Hematol Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"ix520","DOI":"10.1016\/S0923-7534(20)34168-5","article-title":"1618 - in vitro drug-drug interaction studies with the antiemetic drug netupitant and its major metabolites M1 and M2, involving several human cytochrome P450 isoenzymes","volume":"23","author":"Giuliano","year":"2012","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00228-020-03034-4","article-title":"Predicting the presence and mechanism of busulfan drug-drug interactions in hematopoietic stem cell transplantation using pharmacokinetic interaction network-based molecular structure similarity and network pharmacology","volume":"77","author":"Hao","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0438","article-title":"Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea","volume":"20","author":"Ng","year":"2015","journal-title":"Oncologist"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0089","article-title":"Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy","volume":"7","author":"Schwartzberg","year":"2018","journal-title":"J Comp Eff Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx698","article-title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0187","article-title":"Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life","volume":"16","author":"Karthaus","year":"2020","journal-title":"Future Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3866-6","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2018","journal-title":"Support Care Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04697-1","article-title":"Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey","volume":"27","author":"Dielenseger","year":"2019","journal-title":"Support Care Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2750-5","article-title":"Impact and management of chemotherapy\/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists\/oncology nurses and patients: a cross-sectional multinational survey","volume":"23","author":"Vidall","year":"2015","journal-title":"Support Care Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1127","article-title":"Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey","volume":"1","author":"Aapro","year":"2018","journal-title":"Cancer Rep (Hoboken)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1280336\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:45:52Z","timestamp":1700754352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1280336\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":28,"alternative-id":["10.3389\/fonc.2023.1280336"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1280336","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"article-number":"1280336"}}